UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorp ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2020 Earnings Conference Call May 6, 2020 8:30 AM ET Company Participants George Elston - Chief Financial Officer and Head-Corporate Development Nancy Lurker - President and Chief Executive Officer Scott Jones - Chief Commercial Officer Dario Paggiarino - Senior Vice President and Chief Medical Officer Conference Call Participants I-Eh Jen - Laidlaw & Company Andrew D'Silva - B. Riley FBR Yi Chen - H.C. Wainwright Operator Good morning. My name is Shannon and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or other jurisdiction of in ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2019 Earnings Conference Call March 5, 2020 8:30 AM ET Company Participants George Elston – Chief Financial Officer and Head-Corporate Development Nancy Lurker – President and Chief Executive Officer Scott Jones – Chief Commercial Officer Dario Paggiarino – Senior Vice President and Chief Medical Officer Conference Call Participants Dana Flanders – Guggenheim Securities Andrew D'Silva – B. Riley FBR I-Eh Jen – Laidlaw & Company Yi Chen – H.C. Wainwright Operat ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2019 Earnings Conference Call November 7, 2019 8:30 AM ET Company Participants Kimberly Minarovich - Investor Relations, Argot Partners Nancy Lurker - President & Chief Executive Officer Scott Jones - Chief Commercial Officer Conference Call Participants Dana Flanders - Guggenheim Andrew D’Silva - B. Riley Edward Marks - H.C. Wainwright Operator Good morning. My name is Sydney, and I will be your conference operator today. At this time, I would like to welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in ...

EyePoint Pharmaceuticals Third Quarter 2019 Financial Results Conference Call November 7, 2019 On Today's Call Prepared Remarks: Kimberly Minarovich, Argot Partners Nancy Lurker, President & Chief Executive Officer Scott Jones, Chief Commercial Officer Joining for Q&A Session: George Elston, CPA, Consultant and Interim Chief Financial Officer Dario Paggiarino, MD, Senior Vice President & Chief Medical Officer 2 Forward Looking Statements SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF ...

Delivering Innovative Ophthalmic Products to Patients with Serious Eye Disorders Investor Presentation October 2019 NASDAQ: EYPT Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. This presentation is intended for communication for investors only. Nothing in this presentation should be construed as promoting the use o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2019 Earnings Conference Call August 7, 2019 8:30 AM ET Company Participants Kimberly Minarovich - Investor Relations, Argot Partners Nancy Lurker - President & Chief Executive Officer Scott Jones - Chief Commercial Officer Conference Call Participants Andrew D’Silva - B. Riley FBR Yi Chen - H.C. Wainwright Operator Good morning. My name is Lynch, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharm ...